Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models

Experimental Eye Research

Volumn 93, Issue 3, 2011, Pages 250-255

  Krauss, Achim H P ^a   Impagnatiello, Francesco ^b   Toris, Carol B ^c   Gale, David C ^a   Prasanna, Ganesh ^a   Borghi, Valentina ^b   Chiroli, Valerio ^b   Chong, Wesley K M ^a   Carreiro, Samantha T ^a   Ongini, Ennio ^b  

^a PFIZER INC   (United States)

^b Nicox Research Institute   (Italy)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

BOL 303259 X; Glaucoma; IOP; Nitric oxide; Pharmacokinetics; Prostaglandin

Indexed keywords

BOL 303259 X; CYCLIC GMP; LATANOPROST; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CONTROLLED STUDY; CORNEA; DOG; DRUG ACTIVITY; DRUG TISSUE LEVEL; EMBRYO; ENZYME ACTIVITY; GLAUCOMA; HAPLORHINI; HUMAN; HUMAN CELL; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CELL LINE; CILIARY BODY; CYCLIC GMP; DINOPROST; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; GLAUCOMA; GUANYLATE CYCLASE; INTRAOCULAR PRESSURE; IRIS; MACACA FASCICULARIS; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RABBITS; RATS; TONOMETRY, OCULAR;

EID: 80054855842     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.03.001     Document Type: Article

References (26)

1. Borghi V., Bastia E., Guzzetta M., Chiroli V., Toris C.B., Batugo M.R., Carreiro S.T., Chong W.K.M., Gale D.C., Kucera D.J., Liu J., Prasanna G., Ongini E., Krauss A.H.P., Impagnatiello F. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J. Ocul. Pharmacol. Ther. 2010, 26:125-131.
2. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A 6-month, masked, multicenter trial in the United States. Ophthalmology 1996, 103:138-147. The United States Latanoprost Study Group.
3. Camras C.B., Bito L.Z. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha. Curr. Eye Res. 1981, 1:205-209.
4. Camras C.B., Schumer R.A., Marsk A., Lustgarten J.S., Serle J.B., Stjernschantz J., Bito L.Z., Podos S.M. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch. Ophthalmol. 1992, 110:1733-1738.
5. Doganay S., Evereklioglu C., Turkoz Y., Er H. Decreased nitric oxide production in primary open-angle glaucoma. Eur. J. Ophthalmol. 2002, 12:44-48.
6. Gabelt B.T., Kaufman P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 1989, 49:389-402.
7. Galassi F., Renieri G., Sodi A., Ucci F., Vannozzi L., Masini E. Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br. J. Ophthalmol. 2004, 88:757-760.
8. Galle J., Zabel U., Hübner U., Hatzelmann A., Wagner B., Wanner C., Schmidt H.W. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 1999, 127:195-203.
9. Gelatt K.N., MacKay E.O. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous beagle. Vet. Ophthalmol. 2001, 4:283-288.
10. Kotikoski H., Alajuuma P., Moilanen E., Salmenperä P., Oksala O., Laippala P., Vapaatalo H. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J. Ocul. Pharmacol. Ther. 2002, 18:11-23.
11. Lindsey J.D., Kashiwagi K., Kashiwagi F., Weinreb R.N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest. Ophthalmol. Vis. Sci. 1997, 38:2214-2223.
12. Lütjen-Drecoll E., Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α. Exp. Eye Res. 1988, 47:761-769.
13. Nathanson J.A. Nitrovasodilators as a new class of ocular hypotensive agents. J. Pharmacol. Exp. Ther. 1992, 260:956-965.
14. Nathanson J.A., McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest. Ophthalmol. Vis. Sci. 1995, 36:1774-1784.
15. Nathanson J.A., McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest. Ophthalmol. Vis. Sci. 1995, 36:1765-1773.
16. Nilsson S.F.E., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Exp. Eye. Res. 1989, 48:707-716.
17. Orihashi M., Shima Y., Tsuneki H., Kimura I. Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits. Biol. Pharm. Bull. 2005, 28:65-68.
18. Resul B., Stjernschantz J., Selén G., Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv. Ophthalmol. 1997, 41:47-52.
19. Richter M., Krauss A.H., Woodward D.F., Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 2003, 44:4419-4426.
20. Rivera J.L., Bell N.P., Feldman R.M. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr. Opin. Ophthalmol. 2008, 19:102-106.
21. Schuman J.S., Erickson K., Nathanson J.A. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp. Eye Res. 1994, 58:99-105.
22. Sharif N.A., Kelly C.R., Crider J.Y., Williams G.W., Xu S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 2003, 19:501-515.
23. Sjöquist B., Basu S., Byding P., Bergh K., Stjernschantz J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab. Dispos. 1998, 26:745-754.
24. Stewart W.C., Konstas A.G., Nelson L.A., Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008, 115:1117-1122.
25. Stjernschantz J., Selén G., Sjöquist B., Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv. Prostaglandin Thromboxane Leukot. Res. 1995, 23:513-518.
26. Woodward D.F., Burke J.A., Williams L.S., Palmer B.P., Wheeler L.A., Woldemussie E., Ruiz G., Chen J. Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest. Ophthalmol. Vis. Sci. 1989, 30:1838-1842.